Here are five points:
1. Surgeons at three European centers implanted the device in the study’s 16 patients.
2. The study will test the superiority of the Agili-C implant over microfracture and debridement for cartilage or osteochondral defect treatment in knees.
3. CartiHeal plan to enroll at least 250 patients in the study. It hopes to open additional trial sites in the U.S., Europe and Israel.
4. A cell-free, off-the-shelf implant, Agili-C possesses the CE mark.
5. The Agili-C implant is an investigational device in the U.S., only usable in this study, currently.
More articles on devices:
Finally, a single-use, sterile packed ACDF kit simplified for OR efficiency, introducing the Zavation STERICERV Cervical Instruments Kit
TranS1, CU Innovations partner to bring surgeons’ spine concepts to market: 4 takeaways
Alphatec appoints former NuVasive executive as new executive chairman: 8 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.